» Articles » PMID: 9353350

The Binding of T Cell-expressed P-selectin Glycoprotein Ligand-1 to E- and P-selectin is Differentially Regulated

Overview
Journal J Biol Chem
Specialty Biochemistry
Date 1997 Nov 14
PMID 9353350
Citations 19
Authors
Affiliations
Soon will be listed here.
Abstract

The HECA452 carbohydrate epitope, also termed cutaneous lymphocyte antigen, is known to bind to E-selectin and defines a human T cell subset preferentially found in inflamed skin. Activated T cells can express a functional form of the P-selectin glycoprotein ligand-1 (PSGL-1), the major ligand known for P-selectin. Here we show that PSGL-1 can exist in two forms, of which only one carries the HECA452 epitope and binds to E-selectin, while the other only binds to P-selectin. We have analyzed the glycoprotein ligands for E- and P-selectin on the mouse CD8+ T cell clone 4G3 at 4, 8, and 12 days after antigen-specific activation. Only at day 4 did the cells bind to E-selectin, whereas cells at all three activation stages bound to P-selectin. Expression of the HECA452 epitope correlated with E-selectin binding. In affinity isolation experiments, PSGL-1 was isolated as the major ligand by E-selectin-IgG and by P-selectin-IgG; however, PSGL-1 only bound to E-selectin at day 4, whereas it bound to P-selectin at all three activation stages. Immunoprecipitated PSGL-1 from cells at day 4, but not from cells at days 8 and 12, was recognized in immunoblots by monoclonal antibody HECA452. In immunoblots of total extracts of cells at day 4, HECA452 recognized a 240/140-kDa pair of protein bands as the major antigen. These bands could be completely removed by depletion of cell extracts with anti-PSGL-1 antibodies. Our data suggest that the carbohydrate requirements for binding of PSGL-1 to P-selectin differ from those necessary for binding to E-selectin. Furthermore, we conclude that the major glycoprotein carrier for the HECA452 epitope on activated 4G3 cells is PSGL-1.

Citing Articles

Antibody blockade of the PSGL-1 immune checkpoint enhances T-cell responses to B-cell lymphoma.

Pereira J, Arede L, Ferreira F, Matos A, Pereira D, Santos R Leukemia. 2024; 39(1):178-188.

PMID: 39455852 DOI: 10.1038/s41375-024-02446-w.


PSGL-1 decorated with sialyl Lewis promotes high affinity binding of myeloma cells to P-selectin but is dispensable for E-selectin engagement.

ODwyer M, Kirkham-McCarthy L, Cerreto M, Foa R, Natoni A Sci Rep. 2024; 14(1):1756.

PMID: 38243063 PMC: 10798956. DOI: 10.1038/s41598-024-52212-2.


Optimizing human Treg immunotherapy by Treg subset selection and E-selectin ligand expression.

Donnelly C, Dykstra B, Mondal N, Huang J, Kaskow B, Griffin R Sci Rep. 2018; 8(1):420.

PMID: 29323143 PMC: 5765004. DOI: 10.1038/s41598-017-17981-z.


Effector and Regulatory T Cells Roll at High Shear Stress by Inducible Tether and Sling Formation.

Abadier M, Pramod A, McArdle S, Marki A, Fan Z, Gutierrez E Cell Rep. 2017; 21(13):3885-3899.

PMID: 29281835 PMC: 5786164. DOI: 10.1016/j.celrep.2017.11.099.


E-selectin ligands recognised by HECA452 induce drug resistance in myeloma, which is overcome by the E-selectin antagonist, GMI-1271.

Natoni A, Smith T, Keane N, McEllistrim C, Connolly C, Jha A Leukemia. 2017; 31(12):2642-2651.

PMID: 28439107 PMC: 5729350. DOI: 10.1038/leu.2017.123.